bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾

ÃÀ¹ú°©Ö¢Ñо¿Ð­»á£¨AACR£©Äê»á½«ÓÚÍâµØʱ¼ä2024Äê4ÔÂ5-10ÈÕÔÚÃÀ¹úÊ¥µØÑǸç¾ÙÐС£¡£¡£¡£¡£¡£¡£×÷ΪȫÇò×î¾ßÓ°ÏìÁ¦µÄÖ×ÁöÁìÓòѧÊõÊ¢»áÖ®Ò»£¬£¬£¬£¬£¬£¬AACRÄê»á¹Ø×¢Ö×ÁöÑо¿¼°Á¢ÒìµÄ¸÷¸ö·½Ã棬£¬£¬£¬£¬£¬Ðû²¼È«ÇòÖ×ÁöÁìÓòÇ°ÑØÑо¿Ð§¹û¡£¡£¡£¡£¡£¡£¡£¿ËÈÕ£¬£¬£¬£¬£¬£¬AACR ¹Ù·½Ðû²¼ÈëÑ¡Ñо¿ÐÅÏ¢£¬£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÏÂÊô¹«Ë¾Õý´óÌìÇçÒ©Òµ¼¯ÍÅ°²ÂÞÌæÄᣨС·Ö×Ó¶à°ÐµãÊÜÌåÀÒ°±ËἤøÒÖÖƼÁ£©¡¢CD40¼¤¶¯¼ÁTQB2916 ¹²2¿îÁ¢ÒìÒ©µÄ5ÏîÑо¿ÈëÑ¡¡£¡£¡£¡£¡£¡£¡£

ÁÙ´²Ñо¿

 

ALTER-G-001Ò»Ïî¶àÐÐÁС¢¶àÖÐÐÄ¡¢IIÆÚÑо¿——ÐÐÁÐCЧ¹û¸üУº°²ÂÞÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆ°é²»¿ÉÇгý¸ÎתÒÆÏû»¯µÀÖ×Áö

CT213/13 - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C

ͨѶ×÷ÕߣºÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½Ôº ÕÅ¿¡

µÚÒ»×÷ÕߣºÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½Ôº Îâ¬Bçâ

 

ÆÕ±éÆÚСϸ°û·Î°©»¼ÕßÒ»ÏßÃâÒßÍŽữÁƾ­Öκó¶þÏßÖÎÁÆÁÆЧ

5098/20 - Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy

ͨѶ×÷ÕߣºÖйúҽѧ¿ÆѧԺÖ×ÁöÒ½Ôº  Íõ½à

µÚÒ»×÷ÕߣºÖйúҽѧ¿ÆѧԺÖ×ÁöÒ½Ôº  ÍòÈï

 

Ò»ÖÖÐÂÐÍCD40¼¤¶¯¼Á—TQB2916ÔÚÍíÆÚ¶ñÐÔÖ×ÁöÊÜÊÔÕßÖеÄIÆÚÁÙ´²Ñо¿

CT192 / 20 - A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies

Ö÷ÒªÑо¿Õߣº°ÍÒ»

 

»ù´¡Ñо¿

 

·ºËØÌØÒìÐÔÂÑ°×ø18£¨USP18£©Í¨¹ýÎȹÌAurora B¼¤Ã¸¸ÄÉÆ°²ÂÞÌæÄáÔÚ¼××´ÏÙËèÑù°©ÖеÄÄÍÒ©ÐÔ

4665/18 - USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase

ͨѶ×÷ÕߣºÌì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº  Ö£ÏòÇ°

µÚÒ»×÷ÕߣºÌì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº ÇØè¯

 

°²ÂÞÌæÄáÍŽáPARPÒÖÖƼÁ×÷Ϊ°ÐÏòMSLNºÍCD19µÄTGFβ²»Ãô¸ÐµÄCAR-Tϸ°ûÖÎÁÆÔÚÍíÆÚÂѳ²°©µÄÇŽÓÖÎÁÆ

3997/6 - PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer

ͨѶ×÷Õߣº»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº ¸ßÇìÀÙ¡¢·½ÓÂ

µÚÒ»×÷Õߣº»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº ÀÒá

 

AACR¹ÙÍøÒÑÐû²¼±¾½ì¾Û»áÈëÑ¡ÄÚÈÝÎÊÌâ¼°²¿·ÖÑо¿µÄÕªÒªÄÚÈÝ£¬£¬£¬£¬£¬£¬Äú¿ÉµÇ¼ÈçÏÂÍøÖ·Éó²é

https://www.abstractsonline.com/pp8/#!/20272

¾«²ÊÊý¾Ý¼´½«·ºÆ𣬣¬£¬£¬£¬£¬¾´ÇëÆÚ´ý£¡

 

¹ØÓÚ°²ÂÞÌæÄá

 

°²ÂÞÌæÄáÊÇÕý´óÌìÇçÒ©Òµ¼¯ÍÅ×ÔÖ÷Ñз¢µÄÒ»¿î¿Ú·þÐÂÐÍС·Ö×Ó¶à°ÐµãÊÜÌåÀÒ°±ËἤøÒÖÖƼÁ£¨TKI£©£¬£¬£¬£¬£¬£¬ÄÜÓÐÓÃÒÖÖÆVEGFR 1-3¡¢PDGFR α/β¡¢FGFR 1-4¡¢c-KitµÈ¼¤Ã¸£¬£¬£¬£¬£¬£¬Í¨¹ýµ÷¿ØÖ×Áö΢ÇéÐÎÖرà³ÌµÖ´ïÒÖÖÆÖ×ÁöѪ¹ÜÐÂÉú¡¢ÒÖÖÆÖ×ÁöÉú³¤¡¢µ÷¿ØÃâÒß΢ÇéÐεÄ×÷Óᣡ£¡£¡£¡£¡£¡£2018Äê5Ô£¬£¬£¬£¬£¬£¬ÑÎËá°²ÂÞÌæÄὺÄÒ»ñ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú×¼ÉÏÊУ¬£¬£¬£¬£¬£¬ÊÇÖйúÊ׸ö»ñÅúÓÃÓÚÍíÆÚ·ÇСϸ°û·Î°©ÈýÏßÖÎÁƵÄÒ©Îï¡£¡£¡£¡£¡£¡£¡£ÑÎËá°²ÂÞÌæÄὺÄÒÒÑÔÚº£ÄÚ»ñÅúÎå¸ö˳Ӧ֢£ºÈýÏß·ÇСϸ°û·Î°©¡¢ÈýÏßСϸ°û·Î°©¡¢Èí×éÖ¯ÈâÁö¡¢¼××´ÏÙËèÑù°©ºÍ·Ö½âÐͼ××´ÏÙ°©¡£¡£¡£¡£¡£¡£¡£2023Äê1Ô£¬£¬£¬£¬£¬£¬ÑÎËá°²ÂÞÌæÄὺÄҵĵÚÁù¸ö˳Ӧ֢µÄÉÏÊÐÉêÇë»ñCDEÕýʽÊÜÀí£¬£¬£¬£¬£¬£¬ÓÃÓÚÍŽᱴĪËհݵ¥¿¹£¨TQB2450£¬£¬£¬£¬£¬£¬PD-L1ÒÖÖƼÁ£©ºÍ»¯ÁÆÒ»ÏßÖÎÁÆСϸ°û·Î°©¡£¡£¡£¡£¡£¡£¡£2024Äê2Ô£¬£¬£¬£¬£¬£¬ÑÎËá°²ÂÞÌæÄὺÄҵĵÚÆ߸ö˳Ӧ֢µÄÉÏÊÐÉêÇë»ñCDEÕýʽÊÜÀí£¬£¬£¬£¬£¬£¬ÓÃÓÚÍŽᱴĪËհݵ¥¿¹ÖÎÁƸ´·¢ÐÔ»òתÒÆÐÔ×Ó¹¬ÄÚĤ°©¡£¡£¡£¡£¡£¡£¡£

 

¹ØÓÚTQB2916£¨CD40¼¤¶¯¼Á£©

 

CD40¼¤¶¯¼ÁÖ÷Ҫͨ¹ý¼¤»î¿¹Ô­Ìá³Êϸ°û£¨APC£©Ôö½øÃâÒßϸ°ûµÄ»î»¯Ê©Õ¹Ö×ÁöÒÖÖÆ×÷Óᣡ£¡£¡£¡£¡£¡£TQB2916ÊÇ°ÐÏòCD40µÄ¼¤¶¯ÐÍÈ«ÈËÔ´IgG2µ¥¿¹¡£¡£¡£¡£¡£¡£¡£ÌåÍâҩЧѧЧ¹ûÏÔʾTQB2916¿É¼¤»îBϸ°ûºÍÊ÷ͻ״ϸ°û£¬£¬£¬£¬£¬£¬½ø¶ø¼¤»îTϸ°ûÉø͸IFN-γ¡£¡£¡£¡£¡£¡£¡£ÁÙ´²Ç°ÌåÄÚҩЧѧЧ¹ûÏÔʾTQB2916¿ÉÏÔÖøÒÖÖƶ¯ÎïÄ£×ÓµÄÖ×ÁöÉú³¤¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚÈ«ÇòÉÐÎÞCD40¼¤¶¯¼Á»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬Í¬Àà²úÆ·ÔÚÒÈÏÙ°©¡¢Èí×éÖ¯ÈâÁö¡¢ÐþÉ«ËØÁö¡¢Ê³¹Ü°©µÈÁìÓòÕ¹ÏÖ³öÓÐDZÁ¦µÄ¿ª·¢Ô¶¾°¡£¡£¡£¡£¡£¡£¡£